No Picture
News

Takeda forecasts $1.7B loss after Shire integration; Flagship’s preclinical biotech Axcella closes IPO with $71M+ haul

? Takeda?s $TAK first set of financial results since consummating its $62 billion acquisition of Shire is in, and it?s giving analysts a negative surprise. Citing costs for integrating the Ireland-based Shire, the Japanese drugmaker forecasts an operat… […]

No Picture
Events

SDBN Lunch On Us Vendor Show : Jun 20, 2019

Join us in the heart of the La Jolla research mesa, where you can network with a great mix of industry and academia, and still feel the ocean breeze! Don?t forget that Green Acre Nautilus is run by world class chef Brian Malarkey, and the catering will… […]

No Picture
Events

Keiretsu Investor Forum_SoCal : May 20, 2019

Keiretsu Forum is a Global Investment Community of accredited private equity angel investors, venture capitalists and corporate/institutional investors.

We are a worldwide network of capital, resources, and deal flow with 54 chapters on 4 continents. … […]

No Picture
Events

MIT Enterprise Forum: The next wave of technology entrepreneurs; the rise of women’s startups : Jun 19, 2019

Women are founding startups now more than ever before. There was a 68% increase in women launching businesses in the U.S. between 1997 and 2014. That is two-times the rate of businesses owned by men. Further, the likelihood of startups with women exe… […]

No Picture
News

BioLegend Moves Global Headquarters to Newly Constructed, State-of-the-Art Campus in San Diego, California

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/biolegend?src=hash" target="_blank"gt;#biolegendlt;/agt;–BioLegend, leading provider of world-class biological reagents and tools, opens its new global headquarters… […]

No Picture
News

BioLegend Moves Global Headquarters to Newly Constructed, State-of-the-Art Campus in San Diego, California

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/biolegend?src=hash" target="_blank"gt;#biolegendlt;/agt;–BioLegend, leading provider of world-class biological reagents and tools, opens its new global headquarters… […]

No Picture
News

Biopharma Industry Professionals, Regulators, and Patients From Around the World Gather at DIA 2019 to Address Challenges Facing the Development of Therapeutics for Patients

WASHINGTON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/DIA2019?src=hash" target="_blank"gt;#DIA2019lt;/agt;–Amidst these incredibly exciting yet deeply challenging times in global healthcare – from gene therapy, to acc… […]

No Picture
News

California Life Sciences Association Elects Melinda Richter of Johnson & Johnson Innovation – JLABS as New Board Chair, Appoints New Vice Chair, Treasurer

WASHINGTON & SAN FRANCISCO & SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AlexKelly?src=hash" target="_blank"gt;#AlexKellylt;/agt;–California Life Sciences Association Elects New Board Chair, Appoints … […]

No Picture
News

California Life Sciences Association Elects Melinda Richter of Johnson & Johnson Innovation – JLABS as New Board Chair, Appoints New Vice Chair, Treasurer

WASHINGTON & SAN FRANCISCO & SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AlexKelly?src=hash" target="_blank"gt;#AlexKellylt;/agt;–California Life Sciences Association Elects New Board Chair, Appoints … […]

No Picture
News

BioNTech nabs PhI antibody and a new US base out of bankruptcy; Pfizer wins conditional drug OK

? BioNTech is buying MabVax?s labs $MBVX and a clinical asset out of bankruptcy as the German mRNA company establishes a satellite operation in San Diego. The biotech, which has evidently been kicking around a monster IPO, acquired the bankrupt operati… […]

No Picture
News

Neuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson?s Disease and Amyotrophic Lateral Sclerosis

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ALS?src=hash" target="_blank"gt;#ALSlt;/agt;–Neuropore Therapies reenters the clinic with a second therapeutic candidate: NPT520-34 […]